消斑通脉合剂对血管平滑肌细胞增殖和P21waf1/cip1蛋白表达的影响(1)
 |
| 第1页 |
参见附件。
收稿日期:2009-10-14
作者简介:武跃华(1978-),男,辽宁沈阳人,主治医师,2007级博士研究生,研究方向:中西医结合对心血管病的防治。
(1.辽宁中医药大学,辽宁 沈阳 110847;2.辽宁中医药大学附属医院,辽宁 沈阳 110032)
摘 要:目的:探讨中药复方消斑通脉合剂药物血清对血小板源性生长因子(PDGF-BB)诱导的大鼠血管平滑肌细胞(VSMC)增殖与细胞周期分布的影响及相关作用机制。方法:体外培养VSMCs,PDGF-BB刺激VSMCs,采用MTT法检测药物血清对VSMCs增殖的影响;流式细胞仪分析各组细胞周期分布情况;应用Western印迹法检测药物血清对VSMCs中P21waf1/cip1蛋白的表达变化。结果:MTT法显示药物血清呈剂量依赖性抑制VSMCs增值,高剂量与低剂量比较有显著差异(P﹤0.05);流式细胞仪分析结果显示与模型组比较,低剂量与高剂量组明显提高G0/G1期百分率(P﹤0.01)、减少S期百分率(P﹤0.01),低剂量与高剂量组比较有显著差异(P﹤0.05);Western印迹法显示与模型组比较,高剂量与低剂量可明显提高VSMCs中P21waf1/cip1蛋白表达(P﹤0.01),低剂量与高剂量比较有统计学差异(P﹤0.01)。结论:中药复方消斑通脉合剂药物血清通过促进VSMCs中P21waf1/cip1蛋白表达,阻滞VSMCs细胞周期进程,起到抑制VSMCs增殖作用。
关键词:血管平滑肌细胞;P21waf1/cip1;细胞周期
中图分类号:R285.5
文献标识码:A文章编号:
1673-7717(2010)04-0878-03
Effect of XiaoBan TongMai HeJi on Rat Vascular Smooth Muscle Cells Cycle in Vitro
WU Yuehua1,YANG Jiwu2
(1.Liaoning University of TCM,Shenyang 110847,Liaoning,China;2.Affiliated Hospital of Liaoning University of TCM,Shenyang 110032,Liaoning,China)
Abstract:Objective:To study the anti-proliferation and cell cycle blocking effects of the xiao ban tong mai he ji on rat vascular smooth muscle cells(VSMCs) in vitro.Methods:VSMCs were treated with various concentration of the medical serum of xiao ban tong mai he ji for 24 hours. The cell viability was detected by MTT method. Flow cytometry was used to detect the cell cycle. Western blotting was performed to detect the expression of cell cycle regulatory p21 protein. Results: High concentration of the medical serum inhibited the proliferation of VSMCs. Compared with the control group, the expression of P21 protein in the high concentration group were significantly decreased. Conclusion:The medical serum of xiao ban tong mai he ji inhibit of the proliferation and blocks cell cycle progression of VSMCs. These effects are associated with the expression of cell P21 protein.
Key words:vascular smooth muscle cell;p21waf1/cip1;cell cycle
血管平滑肌细胞(vascular smooth muscle cells,VSMCs)的表型转化和增殖是经皮冠状动脉腔内成形术(percutaneous transluminal coronary angioplasty, PTCA)后再狭窄发生的始动因素和中心环节[1],因此在抑制VSMCs增殖成为预防再狭窄的重要途径。中医学理论认为,PTCA术后再狭窄属于“血瘀证”范畴,目前在防治PTCA术后再狭窄的中医药临床治疗中,多以活血化瘀、豁痰祛浊等治法遣药组方[2],以治标为主;考虑到临床此类患者多为中老年人,素体多阳虚,此次组方在活血化瘀基础上添加益气助阳等扶正之品,达到标本兼治之效 ......
您现在查看是摘要介绍页，详见PDF附件(1802kb)。